FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

연구/논문
연구 도서관으로 돌아가기
PubMedPreclinical

Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression.

Marathe Sandesh J, Grey Emily W, Bohm Margaret S, Joseph Sydney C, Ramesh Arvind V, Cottam Matthew A, Idrees Kamran, Wellen Kathryn E, Hasty Alyssa H, Rathmell Jeffrey C
npj metabolic health and disease2025DOI: 10.1038/s44324-025-00054-5
retatrutideLY3437943semaglutide

품질 점수

4/10

참조 문헌

0

피험자

비인간

Peptide Contacts 분석

Study Design

Preclinical research is the foundation of the drug development pipeline. While these findings require human validation, they establish the mechanistic basis that informs dosing strategies, safety profiles, and target identification for future clinical work.

Our Assessment

Quality Assessment: 4/10 — This study contributes useful data but has methodological limitations that warrant caution. The findings are suggestive rather than definitive, and we'd recommend looking for corroborating evidence before drawing strong conclusions.

Findings in Context

The results for retatrutide, LY3437943, semaglutide are encouraging.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: Early-stage evidence for retatrutide, LY3437943, semaglutide. Interesting mechanistic insights, but we'll need human data before drawing practical conclusions.

주요 발견

The study found that retatrutide (LY3437943) significantly reduced pancreatic and lung cancer progression in pre-clinical models, with more pronounced effects compared to single agonist semaglutide. The peptide also induced systemic immune reprogramming leading to durable anti-tumor immunity.

제한 사항

The study is limited by its reliance on animal models which may not fully translate to human clinical outcomes. Additionally, the long-term efficacy and safety of retatrutide in humans are yet to be established.

이 연구를 어떻게 해석해야 하는지

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Animal model results do not automatically translate to humans. Different species metabolize peptides differently, and dosing does not scale linearly.

4

In vitro (cell culture) studies demonstrate biological mechanisms but cannot account for the complexity of whole-organism physiology.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

참조 문헌

Marathe Sandesh J, Grey Emily W, Bohm Margaret S et al.. (2025). Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression.. npj metabolic health and disease. https://doi.org/10.1038/s44324-025-00054-5

PubMed에서 전체 텍스트 확인하기

관련 논문

더 알아보기

이 내용은 교차 검토된 연구를 기반으로 교육 목적용으로 생성되었습니다. 이 내용은 의학적 조언으로 간주되지 않습니다. 피테이드 기반 치료법을 사용하기 전에 항상 자격 있는 의료 전문가와 상담하십시오.